Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_151_библиотеки_им_акад_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
10 Мб
Скачать
☆
286 B. N. H. M. Neeroa et al.
https://t.me/med1917
561 Liu K, Wang ZQ, Wang SJ, Liu P, Qin YH, Ma Y, Li XC, Huo ZJ (2015) Hyaluronic acid-tagged 562 silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation. Int J Nanomedicine 563 10:6445. https://doi.org/10.2147/IJN.S89476 564 Liu W, Zhu Y, Wang F, Li X, Liu X, Pang J, Pan W (2018) Galactosylated chitosan-functionalized 565 mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. R Soc 566 Open Sci 5(12):181027. https://doi.org/10.1098 /rsos.181027 567 Lo PY, Lee GY, Zheng JH, Huang JH, Cho EC, Lee KC (2020) GFP plasmid and chemoreagent 568 conjugated with graphene quantum dots as a novel gene delivery platform for colon cancer 569 inhibition in vitro and in vivo. ACS Appl Bio Mater 3(9):5948–5956. https://doi.org/10.1021/ 570 ACSABM.0C00631/ASSET/IMAGES/MEDIUM/MT0C00631_0010.GIF 571 Low LE, Tan LT, Goh BH, Tey BT, Ong BH, Tang SY (2019) Magnetic cellulose nanocrystal 572 stabilized Pickering emulsions for enhanced bioactive release and human colon cancer therapy. 573 Int J Biol Macromol 127:76–84. https://doi.org/10.1016/J.IJBIOMAC.2019.01.037 574 Lugoloobi I, Maniriho H, Jia L, Namulinda T, Shi X, Zhao Y (2021) Cellulose nanocrystals in 575 cancer diagnostics and treatment. J Control Release 336:207–232. https://doi.org/10.1016/ 576 J.JCONREL.2021.06.004 577 Malik NS, Ahmad M, Minhas MU, Tulain R, Barkat K, Khalid I, Khalid Q (2020) Chitosan/ 578 xanthan gum based hydrogels as potential carrier for an antiviral drug: fabrication, characteri- 579 zation, and safety evaluation. Front Chem 8:50. https://doi.org/10.3389/FCHEM.2020.00050/ 580 BIBTEX 581 Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, Das S, Hanna G, 582 Park W, Chilkoti A, Koning GA (2012) Overcoming limitations in nanoparticle drug delivery: 583 triggered, intravascular release to improve drug penetration into tumors. Cancer Res 72(21): 584 5566–5575. https://doi.org/10.1158/0008-5472.CAN-12-1683 585 Marcelo GA, Montpeyo D, Novio F, Ruiz-Molina D, Lorenzo J, Oliveira E (2020) Luminescent 586 silicon-based nanocarrier for drug delivery in colorectal cancer cells. Dyes Pigments 181: 587 108393. https://doi.org/10.1016/J.DYEPIG.2020.108393 588 Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2020) Engineering 589 precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2):101–124. https://doi.org/ 590 10.1038/s41573-020-0090-8 591 Mkam Tsengam IK, Omarova M, Kelley EG, McCormick A, Bothun GD, Raghavan SR, John VT 592 (2022) Transformation of lipid vesicles into micelles by adding nonionic surfactants: elucidating 593 the structural pathway and the intermediate structures. J Phys Chemi B 126(11):2208–2216. 594 https://doi.org/10.1021/acs.jpcb.1c09685 595 Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, Dorkoosh FA, 596 Handali S (2018) Folic acid-modified liposomal drug delivery strategy for tumor targeting of 597 5-fluorouracil. Eur J Pharm Sci 114:166–174. https://doi.org/10.1016/J.EJPS.2017.12.011 598 Näkki S, Wang JT, Wu J, Fan L, Rantanen J, Nissinen T, Kettunen MI, Backholm M, Ras RH, 599 Al-Jamal KT, Lehto VP (2019) Designed inorganic porous nanovector with controlled release 600 and MRI features for safe administration of doxorubicin. Int J Pharm 554:327–336. https://doi. 601 org/10.1016/J.IJPHARM.2018.10.074 602 Naseri N, Valizadeh H, Zakeri-Milani P (2015) Solid lipid nanoparticles and nanostructured lipid 603 carriers: structure, preparation and application. Adv Pharm Bull 5(3):305. https://doi.org/ 604 10.15171/APB.2015.043 605 Neerooa BNHM, Ooi LT, Shameli K, Dahlan NA, Islam JMM, Pushpamalar J, Teow SY (2021) 606 Development of polymer-assisted nanoparticles and nanogels for cancer therapy: an update. 607 Gels 7(2):60. https://doi.org/10.3390/gels7020060 608 Ngwabebhoh FA, Erdagi SI, Yildiz U (2018) Pickering emulsions stabilized nanocellulosic-based 609 nanoparticles for coumarin and curcumin nanoencapsulations: in vitro release, anticancer and 610 antimicrobial activities. Carbohydr Polym 201:317– 328. https://doi.org/10.1016/J.CARBPOL. 611 2018.08.079 612 Osorio M, Martinez E, Naranjo T, Castro C (2020) Recent advances in polymer nanomaterials for 613 drug delivery of adjuvants in colorectal cancer treatment: a scientific-technological analysis and 614 review. Molecules 25(10):2270. https://doi.org/10.3390/MOLECULES25102270
Development of Biocompatible Nanocarriers for the Treatment of Colorectal Cancer 287
https://t.me/med1917
615Pang SW, Awi NJ, Armon S, Lim WWD, Low JSH, Peh KB, Peh SC, Teow SY (2019) Current 616update of laboratory molecular diagnostics advancement in management of colorectal cancer 617(CRC). Diagnostics 10(1):9. https://doi.org/10.3390/diagnostics10010009 618Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9):7442–7447. 619https://doi.org/10.1021/nn404501g 620Pishavar E, Ramezani M, Hashemi M (2019) Co-delivery of doxorubicin and TRAIL plasmid by 621modified PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation. Drug Dev 622Ind Pharm 45(12):1931–1939. https://doi.org/10.1080/03639045.2019.1680995 623Prajapati SK, Jain A, Shrivastava C, Jain AK (2019) Hyaluronic acid conjugated multi-walled 624carbon nanotubes for colon cancer targeting. Int J Biol Macromol 123:691–703. https://doi.org/
62510.1016/J.IJBIOMAC.2018.11.116 626Priyadarshi K, Shirsath K, Waghela NB, Sharma A, Kumar A, Pathak C (2021) Surface modified 627PAMAM dendrimers with gallic acid inhibit, cell proliferation, cell migration and inflammatory 628response to augment apoptotic cell death in human colon carcinoma cells. J Biomol Struct Dyn 62939(18):6853–6869. https://doi.org/10.1080/07391102.2020.1802344 630Pushpamalar J, Meganathan P, Tan HL, Dahlan NA, Ooi LT, Neerooa BNHM, Essa RZ, 631Shameli K, Teow SY (2021) Development of a polysaccharide-based hydrogel drug delivery 632system (DDS): an update. Gels 7(4):153. https://doi.org/10.3390/gels7040153 633Rajabi M, Mousa A (2016) Lipid nanoparticles and their application in nanomedicine. Curr Pharm 634Biotechnol 17(8):662–672. https://doi.org/10.2174/1389201017666160415155457 635Ramezani P, Abnous K, Taghdisi SM, Zahiri M, Ramezani M, Alibolandi M (2020) Targeted 636MMP-2 responsive chimeric polymersomes for therapy against colorectal cancer. Colloids Surf 637B Biointerfaces 193:111135. https://doi.org/10.1016/J.COLSURFB.2020.111135 638Ramzy L, Metwally AA, Nasr M, Awad GA (2020) Novel thymoquinone lipidic core nanocapsules 639with anisamide-polymethacrylate shell for colon cancer cells overexpressing sigma receptors. 640Sci Rep 10(1):1–15. https://doi.org/10.1038/s41598-020-67748-2 641Rao S, Prestidge CA (2016) Polymer-lipid hybrid systems: merging the benefits of polymeric and 642lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv 13(5):691–707. 643https://doi.org/10.1517/17425247.2016.1151872 644Reimondez-Troitiño S, González-Aramundiz JV, Ruiz-Bañobre J, López-López R, Alonso MJ, 645Csaba N, de la Fuente M (2019) Versatile protamine nanocapsules to restore miR-145 levels and 646interfere tumor growth in colorectal cancer cells. Eur J Pharm Biopharm 142:449–459. https:// 647doi.org/10.1016/J.EJPB.2019.07.016 648Rideau E, Dimova R, Schwille P, Wurm FR, Landfester K (2018) Liposomes and polymersomes: a 649comparative review towards cell mimicking. Chem Soc Rev 47(23):8572–8610. https://doi.org/
65010.1039/C8CS00162F 651Sabit H, Abdel-Hakeem M, Shoala T, Abdel-Ghany S, Abdel-Latif MM, Almulhim J, Mansy M 652(2022) Nanocarriers: a reliable tool for the delivery of anticancer drugs. Pharmaceutics 14(8):
6531566. https://doi.org/10.3390/pharmaceutics14081566 654Sandri SR, Bonferoni MC, Ferrari F, Mori M, Caramella C (2012) The role of chitosan as a 655mucoadhesive agent in mucosal drug delivery. J Drug Deliv Sci Technol 22(4):275–284. https:// 656doi.org/10.1016/S1773-2247(12)50046-8 657Sauraj Kumar SU, Kumar V, Priyadarshi R, Gopinath P, Negi YS (2018) pH-responsive prodrug 658nanoparticles based on xylan-curcumin conjugate for the efficient delivery of curcumin in 659cancer therapy. Carbohydr Polym 188:252–259. https://doi.org/10.1016/j.carbpol.2018.02.006 660Scioli Montoto S, Muraca G, Ruiz ME (2020) Solid lipid nanoparticles for drug delivery: pharma- 661cological and biopharmaceutical aspects. Front Mol Biosci 7:319. https://doi.org/10.3389/ 662FMOLB.2020.587997/BIBTEX 663Serini S, Cassano R, Corsetto PA, Rizzo AM, Calviello G, Trombino S (2018) Omega-3 PUFA 664loaded in resveratrol-based solid lipid nanoparticles: physicochemical properties and antineo- 665plastic activities in human colorectal cancer cells in vitro. Int J Mol Sci 19(2):586. https:// 666doi.org/10.3390/IJMS19020586
288 B. N. H. M. Neeroa et al.
https://t.me/med1917
667 Shabbir R, Mingarelli M, Cabello G, Van Herk M, Choudhury A, Smith TA (2021) EGFR targeting 668 of [177Lu] gold nanoparticles to colorectal and breast tumour cells: affinity, duration of binding 669 and growth inhibition of Cetuximab-resistant cells. J King Saud Univ Sci 33(7):101573. https:// 670 doi.org/10.1016/J.JKSUS.2021.101573 671 Shad PM, Karizi SZ, Javan RS, Mirzaie A, Noorbazargan H, Akbarzadeh I, Rezaie H (2020) Folate 672 conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor 673 and apoptosis efficacy on colorectal cancer cells (HT29 cell line). Toxicol In Vitro 65(1): 674 104756. https://doi.org/10.1016/J.TIV.2019.104756 675 Shen MY, Liu TI, Yu TW, Kv R, Chiang WH, Tsai YC, Chen HH, Lin SC, Chiu HC (2019) 676 Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/ 677 thermotherapy delivery system for local treatment of colon cancer. Biomaterials 197:86–100. 678 https://doi.org/10.1016/J.BIOMATERIALS.2019.01.019 679 Sherje AP, Jadhav M, Dravyakar BR, Kadam D (2018) Dendrimers: A versatile nanocarrier for 680 drug delivery and targeting. Int J Pharm 548(1):707–720. https://doi.org/10.1016/j.ijpharm. 681 2018.07.030 682 Singhvi G, Hans N, Shiva N, Dubey SK (2019) Xanthan gum in drug delivery 683 applications. In: Natural polysaccharides in drug delivery and biomedical applications, 684 pp 121–144. https://doi.org/10.1016/B978-0-12-817055-7.00005-4 685 Sookkasem A, Chatpun S, Yuenyongsawad S, Wiwattanapatapee R (2015) Alginate beads for 686 colon specific delivery of self-emulsifying curcumin. J Drug Deliv Sci Technol 29:159–166. 687 https://doi.org/10.1016/J.JDDST.2015.07.005 688 Sun M, Wang T, Li L, Li X, Zhai Y, Zhang J, Li W (2021) The application of inorganic 689 nanoparticles in molecular targeted cancer therapy: EGFR targeting. Front Pharmacol 12: 690 1454. https://doi.org/10.3389/FPHAR.2021.702445/BIBTEX 691 Teow SY, Liew K, Ali SA, Khoo ASB, Peh SC (2016) Antibacterial action of curcumin against 692 Staphylococcus aureus: a brief review. J Trop Med 2016:2853045. https://doi.org/10.1155/ 693 2016/2853045 694 Tomeh MA, Hadianamrei R, Zhao X (2019) A review of curcumin and its derivatives as anticancer 695 agents. Int J Mol Sci 20(5):1033. https://doi.org/10.3390/ijms20051033 696 Ways TM, Lau WM, Khutoryanskiy VV (2018) Chitosan and its derivatives for application in 697 mucoadhesive drug delivery systems. Polymers 10(3):267. https://doi.org/10.3390/ 698 POLYM10030267 699 Wei Y, Gu X, Sun Y, Meng F, Storm G, Zhong Z (2020) Transferrin-binding peptide functionalized 700 polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. J Control 701 Release 319:407–415. https://doi.org/10.1016/J.JCONREL.2020.01.012 702 Wu P, Zhou Q, Zhu H, Zhuang Y, Bao J (2020) Enhanced antitumor efficacy in colon cancer using 703 EGF functionalized PLGA nanoparticles loaded with 5-fluorouracil and perfluorocarbon. BMC 704 Cancer 20(1):1–10. https://doi.org/10.1186/s12885-020-06803-7 705 Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 706 14(10):101174. https://doi.org/10.1016/j.tranon.2021.101174 707 Xiao B, Viennois E, Chen Q, Wang L, Han MK, Zhang Y, Zhang Z, Kang Y, Wan Y, Merlin D 708 (2018) Silencing of intestinal glycoprotein CD98 by orally targeted nanoparticles enhances 709 chemosensitization of colon cancer. ACS Nano 12(6):5253–5265. https://doi.org/10.1021/ 710 acsnano.7b08499 711 Xie YH, Chen YX, Fang JY (2020) Comprehensive review of targeted therapy for colorectal 712 cancer. Sig Transduct Target Ther 5:22. https://doi.org/10.1038/s41392-020-0116-z 713 Yadav HK, Almokdad AA, Sumia IM, Debe MS (2019) Polymer-based nanomaterials for drug- 714 delivery carriers. nanocarriers for drug delivery. In: Nanoscience and nanotechnology in drug 715 delivery, pp 531–556. https://doi.org/10.1016/B978-0-12-814033-8.00017-5
Development of Biocompatible Nanocarriers for the Treatment of Colorectal Cancer 289
https://t.me/med1917
716Ye H, Shen Z, Yu L, Wei M, Li Y (2018) Manipulating nanoparticle transport within blood flow 717through external forces: An exemplar of mechanics in nanomedicine. Proc Math Phys 718474(2211):20170845. https://doi.org/10.1098/rspa.2017.0845 719Yingchoncharoen P, Kalinowski DS, Richardson DR (2016) Lipid-based drug delivery systems in 720cancer therapy: what is available and what is yet to come. Pharmacol Rev 68(3):701. https://doi. 721org/10.1124/PR.115.012070 722Yusefi M, Shameli K (2021) Nanocellulose as a vehicle for drug delivery and efficiency of 723anticancer activity: a short-review. J Nanosci Nanotechnol 1(1):30–43. https://doi.org/
72410.37934/JRNN.1.1.3043 725Zheng B, Chen L, Pan CC, Wang JZ, Lu GR, Yang SX, Xue ZX, Wang FY, Xu CL (2018) Targeted 726delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy. 727Nanomedicine 13(7):769–785. https://doi.org/10.2217/nnm-2017-0345
Challenges of Onco-therapeutics
https://t.me/med1917
in Early-Onset Colorectal Cancer
Katie Doogan, Alexandra M. Zaborowski, and Des C. Winter
Abstract
The incidence of colorectal cancer among adults aged less than 50 is rising. Patients with early-onset colorectal cancer are more likely to present with advanced disease stage with requirements for multimodal treatment. Younger patients appear to have higher rates of treatment-related toxicities, giving rise to unique challenges for these patients. The impact of treatment-related morbidity on quality of life can be overlooked. Survivorship issues are increasingly relevant owing to the potential for long-term survival following treatment. Striking a balance between treating early-onset colorectal cancer while preserving bowel, bladder, sexual function, and fertility is challenging yet imperative.
Keywords
Chemotherapy · Early-onset colorectal cancer · Immunotherapy · Radiotherapy
1 Introduction
The incidence of early-onset colorectal cancer (age younger than 50) has increased globally. Distinct clinical and pathological patterns have emerged. Patients with early-onset colorectal cancer (EOCRC) frequently display unfavourable histopath­ological features and have advanced disease stage at presentation (Zaborowski et al.
2021a). Despite this, they have better or equivalent short-term and long-term
survival than patients with late-onset disease (Kneuertz et al. 2015; Saraste et al.
2020; Zaborowski et al. 2021a; AlZaabi et al. 2022). Young patients are also more
K. Doogan (✉) · A. M. Zaborowski · D. C. Winter Centre for Colorectal Disease, St Vincent’s University Hospital, Dublin, Ireland e-mail: doogank@tcd.ie
#
The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 Interdisciplinary Cancer Research, https://doi.org/10.1007/16833_2023_148 Published online: 15 February 2023
291
292 K. Doogan et al.
https://t.me/med1917
likely to receive neoadjuvant chemoradiotherapy and adjuva nt chemotherapy than their older counterparts and are also more likely to receive neoadjuvant and adjuvant therapies outside of current treatment guidelines with minimal adjusted survival gain (Kneuertz et al. 2015; Zaborowski et al. 2021a). The administration of intense treatment may be related to better overall performance status and more advanced disease stage at presentation (Bahadoer et al. 2022).
Receiving a cancer diagnosis at a younger age comes with unique challenges compared to those in older age groups. Obstacles facing young patients with CRC arise not only from the diagnosis and disease process but also from the prescribed treatment. Patients with EOCRC are more likely to develop both disease- and treatment-related long-term side effects (AlZaabi et al. 2022). These distressing consequences are often under-recognised, with limited commentary in the literature. Issues particularly pertinent to the young patients include fertility and family planning concerns, responsibilities to young children, disruption to academic, work­ing life and career ambitions, financial instability, and psychological impacts includ­ing a premature confrontation with mortality and a sense of lack of life completion or attainment of life goals/milestones (Perl et al. 2016; AlZaabi et al. 2022; Eng et al.
2022). Younger age is a significant predictor for increased financial burden (Simard
et al. 2019). Young patients also report more psychological symptoms compared to their older counterparts, including higher anxiety levels and negative body image (Bailey et al. 2015).
With the focus on achieving disease control, the impact of treatment-related morbidity on quality of life may be overlooked. Patient expectations that complications may be only mild or temporary can make it more difficult to cope with severe symptoms (Lim et al. 2021). Furthermore, survivors can attribute symptoms with potential disease progression or recurrence triggering distress (Lim et al. 2021). As survivorship improves, it is pertinent to consider quality of life when deciding on treatment strategies. Clinicians should understand the challenges of onco-therapeutics in managing early-onset colorectal cancers.
2 Total Neoadjuvant Therapy and the Potential
for Nonoperative Treatment
Trimodal treatment for rectal cancer (surgery, radiotherapy, and chemotherapy) achieves good local control rates and long-term survival; however, multimodal treatment is also associated with significant morbidity. Many long-term sequelae are attributable to surgical resection. Patients achieving a pathological complete response (pCR) following neoadjuvant therapy have lower local recurrence and improved survival rates compared with those with a non-pCR (Park et al. 2012). This therefore questions the added benefit of surgery in those who achieve a pCR. Nonoperative management for patients with rectal cancer who achieve complete clinical response following neoadjuvant chemotherapy is feasible, and surgical resection may not lead to improved outcomes in select cases (Habr-Gama et al. 2004). Total neoadjuvant therapy (TNT) where patients receive full-dose
Challenges of Onco-therapeutics in Early-Onset Colorectal Cancer 293
https://t.me/med1917
chemotherapy upfront in addition to radiotherapy has emerged as a potential option to facilit ate organ preservation. This approach may be particularly attractive among young patients (Eng et al. 2022). A substantial proportion of patients who undergo surgery for EOCRC report a reduction in quality of life, and functional impairment is unfortunately common. Patients with EOCRC are more likely to undergo more complex operations for early-stage and metastatic disease (Siegel et al. 2020). Dysfunction related to operative intervention can involve bowel-, urogenital-, and fertility-related function (Bailey et al. 2015; Eng et al. 2022). Surgery can also trigger lifestyle changes and inhibit participation in hobbies and socialising (Lim et al. 2021). Therefore, the potential for nonoperative management is an attractive option, enabling younger patients to evade potentially long-lasting bowel, urinary, and sexual dysfunction associated with surgical resection. It is also of significant consideration to EOCRC cancer patients who may want to avoid a stoma, temporary, or permanent and the negative implications it can pose on quality of life, including lower body image and poorer social activity, higher levels of depression and anxiety, more pronounced sexual difficulties, sleep disturbance, and delayed return to work (Baldwin et al. 2009; Lim et al. 2021; Cotrim and Pereira 2008; Traa et al. 2012; Reese et al. 2014; den Bakker et al. 2020).
Advances in multimodality therapy have led to significantly improved local control in rectal cancer. TNT should be considered in patients with high-risk locally advanced rectal cancer owing to improved chemotherapy compliance in addition to improved disease control (Zaborowski et al. 2019; Kong et al. 2021). Chemotherapy is poorly tolerated after surgery for rectal cancer, and up to 50% of patients may not complete planned cycles, and 25% may not receive any adjuvant chemotherapy (Bosset et al. 2014). Additionally, TNT appears to have reduced toxicity compared with adjuvant chemotherapy (REACCT Collaborative 2022a, b, c). Radiotherapy has been shown to be more effective in the neoadjuvant setting, with greater compliance rates than in the adjuvant setting (Beets 2021). TNT has ability to overcome suboptimal complicate rates consistently observed with adjuvant therapy (Zaborowski et al. 2019). Consistently poor adherence has been demonstrated. Similar long-term oncological outcomes have been shown for patients with clinical complete response and pathological complete response, adding to the attractiveness of this option in suitable young candidates (Smith et al. 2012; Bahadoer et al. 2022).
One of the most promising potential advantages of TNT is the earlier delivery of high-dose systemic chemotherapy aimed at eradicating occult micrometastases and thereby reducing distant failure and improving long-term survival. Distant failure rates remain high in rectal cancer, ranging between 20% and 30%, and remain the most common form of treatment failure in patients with locally advanced rectal cancer. A further potential advantage of TNT is that early optimisation of systemic therapy may increase disease regression and improve pathological response rates. Disease progression during high-dose chemotherapy is suggestive of unfavourable treatment-resistant biology, in which case resection may be futile. In contrast, in patients with marked tumour regression, organ preservation may be an appropriate option, thereby facilitating a more selective practice of surgery (Zaborowski et al.
2019).
294 K. Doogan et al.
https://t.me/med1917
An important advantage of TNT is the potential to avoid radical surgical inter­vention. Both the safety and feasibility of offering a strict surveillance strategy has been established in patients with a clinical complete response (cCR) after neoadjuvant therapy (van der Valk et al. 2018; Garcia-Aguilar et al. 2020, 2022). However, there remains hesitancy to offer organ preservation treatment to those aged under 50 owing to a potentially higher oncological risk. Recent data comparing young patients to their older counterparts following a watch-and-wait strategy after a cCR demonstrated no additional oncological risk, with comparable disease-specific survival, risk of local recurrence, and distant metastases (Bahadoer et al. 2022). While undergoing surgical resection provides greater oncological certainty owing to histological confirmation of tumour response, a watch-and-wait approach still should be discussed with patients when a cCR is demonstrated after treatment based on current evidence.
Limitations associated with a TNT strategy exist. Delay to definitive surgery is a particular concern in patients who have poor response to CRT. In those with little or no response to neoadjuvant CRT, a longer interval to surgery is associated with worse overall and disease-free survival (Deidda et al. 2021). The aim should be to identify poor responder early and proceed with surgery without delay. Adding to this, neoadjuvant therapy can have a negative impact on performance status. Admin­istration of full-dose systemic therapy may significantly affect fitness for surgery, potentially resultin g in a prolonged interval to resection and/or higher postoperative morbidity rates (Ludmir et al. 2017). In addition, delaying surgery may allow local disease progression, resulting in more technically challenging dissection, increased perioperative complications, and poorer overall survival (Zaborowski et al. 2019).
3 Challenges and Consequences of Pelvic Radiotherapy
Pelvic radiotherapy can cause bowel, urinary tract, and sexual organ dysfunction. The term pelvic radiation disease (PRD) has been used to describe this, which can be defined as ‘transient or longer-term problems, ranging from mild to very severe, arising in non-cancerous tissues resulting from radiotherapy treatment to a tumour located in the pelvis’ (Andreyev et al. 2011). Symptoms can range in severity, from mild self-limiting conditions to debilitating symptoms with high morbidity. Acute toxicity, occurring in the first 3 months following treatment, encompasses an inflammatory response to radiation exposure, whereas small vessel disease, ische­mia, and fibrosis underpin later toxicities (Dalsania et al. 2021). Despite newer, more precise techniques in radiation delivery to the pelvis and rectum, almost all patients still develop acute adverse effects (Tonneau et al. 2021).
Gastrointestinal toxicity is a common consequence of pelvic irradiation and can be highly problematic for patients. Symptoms can include rectal bleeding, faecal incontinence, and faecal urgency. Gastrointestinal symptoms have the most signifi­cant impact on quality of life after pelvic radiation (Andreyev et al. 2010). Almost all patients receiving radical pelvic radiotherapy have a permanent change in bowel function, with a reduction in quality of life in 50% of patients and severe effects in up
Challenges of Onco-therapeutics in Early-Onset Colorectal Cancer 295
https://t.me/med1917
to one-third of patients (Andreyev 2015). Radiation-induced gastrointestinal symptoms affect as many patients each year as develop inflammatory bowel disease, and as cancer therapy continues to improve with increased survivorship, gastrointes­tinal radiation toxicity will become a more prevalent health issue (Andreyev 2015; Dalsania et al. 2021). Improvement techniques in radiation therapy in attempts to reduce the amoun t of exposure to adjacent normal tissue have led to reduction in acute toxicity; however, reduction of later toxicity is yet to be demonstrated (Klopp et al. 2018). Concurrent chemotherapy and prior abdominal surgery contribute to the development of longer-term complications (Dalsania et al. 2021). Toxic effects can be progressive, with the need for operative intervention to manage these complications increasing over time (Andreyev et al. 2011). Bowel dysfunction and unpredictability, due to radiotherapy in addition to surgical intervention, cause heightened anxiety and fear, exacerbating functional limitations and restrictions survivors place on themselves, for example, alternating diet to accommodate bowel function, staying at home, or near a toilet at all times (Lim et al. 2021).
Urological complications too occur following pelvic radiotherapy. Due to their location, there is unavoidable radiation exposure of the bladder, urethra, and distal ureters. This can lead to a broad range of debilitating outcomes for patients including radiation cystitis; lower urinary tract dysfunction including frequency, urgency, and nocturia; fistula formation; and stricture formation (Lobo et al. 2018). There does not appear to be any difference in risk of developing urinary dysfunction between short course and long course protocols (Guckenberger et al. 2013; Bregendahl et al. 2015). Radiation-induced damage appears to cause higher rates of dysfunction than that caused by operative intervention (Pollack et al. 2006; Beraldo et al. 2015). Manage­ment of these symptoms places a tremendous burden on the healthcare system, disproportionally using more resources. Patients who require admission to hospital under urology services to manage these complications have longer lengths of hospital stays, have more operations, require more emergency surgeries, and have higher readmission rates than other urology patients (Handmer et al. 2020).
Reproductive health and fertility are important considerations in young cancer patients, and it is pertinent to address sexual health concerns early to limit wider psychosocial effects (Reese et al. 2018). With the potential for prolonged survivor­ship in young patients and with sexual health playing a pivotal role in quality of life, it is increasingly important to recognise these challenges. Rectal cancer patients tend to report greater levels of sexual impairment; however, this may be due to combina­tion effects of multimodal treatments including the effects of preoperative radiother­apy (Reese et al. 2018 ). Sexual dysfunction can act as an obstacle to reproduction. Following radiothera py, almost 50% of men and 25% of women have difficulty maintaining sexual relations (Brown et al. 2016). Future fertility is exceptionally important to young cancer survivors (Teh et al. 2014). Multimodal treatment with a combination of radiotherapy and chemotherapy will induce higher rates of gonadotoxicity than either modality alone (Vakalopoulos et al. 2015). Pelvic radio­therapy can have detrimental effects on fertility in women, including premature ovarian failure and permanent infertility (Spanos et al. 2008; Eng et al. 2022). Pelvic radiation utilised in the treatment of rectal cancer exposed the ovaries to reasonable
296 K. Doogan et al.
https://t.me/med1917
doses of radiation, with a dose-dependent relationship between radiation and prema­ture menopause (Maltaris et al. 2007; Wo and Viswanathan 2009). In addition, the uterus is also the victim of radiation-included damage. If conception is achieved, pregnancy maintenance is impacted by the development of fibrosis and a reduction in uterine blood flow, uterine volume, and elasticity as a consequence of radiation exposure (Maltaris et al. 2007; Teh et al. 2014). Miscarriage, placental abnormalities, and premature labour are consequences (Spanos et al. 2008;Wo and Viswanathan 2009). In addition, radiation therapy can also lead to sterility in the male patient, due to effects on spermatogenesis (Vakalopoulos et al. 2015; Eng et al. 2022). The impact of treatment on fertility must be explored with patients, and options for fertility preservation discussed, particula rly in the era of increased access to assisted reproductive technology. Data on how to best manage these toxicities is lacking, with a limited evidence base for proposed treatments. This is true in the management of rectal tumours and also applies to other pelvic malignancies where radiotherapy forms part of the treatment plan (Dalsania et al. 2021). However, with the emerging increased understanding of the underlying aetiology and molecular mechanisms of radiation-induced toxicity, and ongoing efforts to focus the field of radiation delivery, one can hope this can shed a light on effective treatment mechanisms and reduce the burden of radiation-induced morbidity (Andreyev
2015).
4 Implications of Chemotherapeutics in Early-Onset
Colorectal Cancer
Younger patients are more likely to receive more intensive adjuvant chemotherapy with minimal survival gains (Kneuertz et al. 2015; Eng et al. 2022). Currently there is no difference in treatment recommendations between early- and later-onset patients. Multiple acute toxicities can be problematic in young patients including nausea, vomiting, acne, and alopecia (Eng et al. 2022). A consequence of this is the impairment of typical day-to-day functioning. Loss of appetite and changes in taste are also distressing side effects of chemotherapy agents (Ho et al. 2016). Alternations in cognition are also of concern, impacting on occupational, familial, and social life (Schagen et al. 2022). Psychological unmet needs are of greater prevalence than physical unmet needs in advanced colorectal cancer patients receiv­ing chemotherapy (Sakamoto et al. 2017). Lower self-esteem, reduced social func­tioning, and negative body image all negatively affect quality of life in patients receiving chemotherapy (Eng et al. 2022).
Long-term sequelae and chronic side effects of chemotherapy can have a sub­stantial and ongoing impact on quality of life (Eng et al. 2022). Peripheral neuropa­thy is a leading cause of long-term morbidity, with chemotherapy-induced peripheral neuropathy having a negative association with quality of life in cancer survivors, with the potential for symptoms to persist for years following cessation of treatment